Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
Journal of Clinical Oncology · 10.11.2026
DOI: 10.1200/jco-26-02650 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 10.11.2026. Verfasst von Wei Jiang und 24 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli….
Abstract (Originalsprache)
PURPOSE To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
- American Society of Clinical Oncology, Alexandria, VA, USA.
- National Cancer Centre Singapore/Duke-NUS Medical School, Singapore.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Stanford University School of Medicine, Stanford, CA, USA.
- Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Wei Jiang, Nofisat Ismaila, Melvin Lk Chua, Quynh-Thu Le, A Dimitrios Colevas, Nabil F Saba, Kevin Harrington, Shao Hui Huang, Anthony Tc Chan, Christine H Chung, Gregorius Ben Prajogi, Wen-Feng Fang, Su-Fang Qiu, Yi-Jun Hua, Qing-Qing Cai, Brigette Ma, Yu-Pei Chen
Zitieren
APA
Jiang, W., Ismaila, N., Chua, M. L., Haddad, R., Le, Q. T., Colevas, A. D., Saba, N. F., Harrington, K., Huang, S. H., Chan, A. T., Chung, C. H., Prajogi, G. B., Ishak, W. Z. W., Siu, L. L., Fang, W. F., Qu, S., Qiu, S. F., Hua, Y. J., Cai, Q. Q., …, & Ma, J. (2026). Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-02650
Vancouver
Jiang W, Ismaila N, Chua ML, Haddad R, Le QT, Colevas AD, et al. Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-02650
BibTeX
@article{Jiang2026,
author = {Jiang, Wei and Ismaila, Nofisat and Chua, Melvin Lk and Haddad, Robert and Le, Quynh-Thu and Colevas, A Dimitrios and Saba, Nabil F and Harrington, Kevin and Huang, Shao Hui and Chan, Anthony Tc and Chung, Christine H and Prajogi, Gregorius Ben and Ishak, Wan Zamaniah Wan and Siu, Lillian L and Fang, Wen-Feng and Qu, Song and Qiu, Su-Fang and Hua, Yi-Jun and Cai, Qing-Qing and Whitley, Alexander C and Lam, Shu Wing Jack and Siahaan, Yosephtri and Ma, Brigette and Chen, Yu-Pei and Ma, Jun},
title = {Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-02650}
}
EUVIMED